Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Oregon ,Steven Kelly ,Leadership Team ,Company Phase ,Vivo Oncology Program Moderna Collaboration ,Prnewswire Carisma Therapeutics Inc ,Fred Hutchinson Cancer Center ,Exchange Commission ,Drug Administration ,University Of Pennsylvania Abramson Cancer Center ,Carisma Therapeutics Inc ,Sarah Cannon Cancer Research Institute ,City Of Hope National Medical Center ,Oregon Health Science University ,Company Quarterly Report On Form ,Md Anderson Cancer Center ,Exchange Commission On ,Nasdaq ,Chief Executive Officer ,Vivo Oncology Program ,Moderna Collaboration ,Eric Siegel ,General Counsel ,Corporate Secretary ,Terry Shields ,Senior Vice President ,Russell Microcap ,Investigational New Drug ,Pennsylvania Abramson Cancer Center ,Hope National Medical Center ,Cancer Center ,Oregon Health ,Science University ,Fred Hutchinson Cancer ,Private Securities Litigation Reform Act ,Carisma Therapeutic ,Quarterly Report ,Convertible Preferred Stock ,Stockholder Equity ,Carisma Therapeutics ,Consolidated Statements ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Earnings Forecasts Amp Projections ,Earnings ,